Source 1primary paper2025MED
Toolkit/KEAP1-recruiting PROTACs
KEAP1-recruiting PROTACs
Also known as: KEAP1-based PROTACs
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
The development of KEAP1-recruiting PROTACs utilizing ligands derived from different classes of known KEAP1 inhibitors-including short peptides, covalent small molecules (e.g., CDDO derivatives), and non-covalent inhibitors (e.g., KI696)-is discussed.
Usefulness & Problems
Why this is useful
These PROTACs recruit KEAP1 to drive ubiquitination and proteasomal degradation of selected target proteins. The abstract highlights examples directed at BRD4, CDK9, FAK, Tau, and KEAP1 itself.; recruiting KEAP1 for targeted protein degradation; degrading targets including BRD4, CDK9, FAK, Tau, and KEAP1
Source:
These PROTACs recruit KEAP1 to drive ubiquitination and proteasomal degradation of selected target proteins. The abstract highlights examples directed at BRD4, CDK9, FAK, Tau, and KEAP1 itself.
Source:
recruiting KEAP1 for targeted protein degradation
Source:
degrading targets including BRD4, CDK9, FAK, Tau, and KEAP1
Problem solved
They provide an alternative E3 ligase recruitment strategy intended to expand the design space for targeted protein degradation.; provides a KEAP1-based route to targeted protein degradation; broadens E3 ligase recruiter options in PROTAC design
Source:
They provide an alternative E3 ligase recruitment strategy intended to expand the design space for targeted protein degradation.
Source:
provides a KEAP1-based route to targeted protein degradation
Source:
broadens E3 ligase recruiter options in PROTAC design
Problem links
broadens E3 ligase recruiter options in PROTAC design
LiteratureThey provide an alternative E3 ligase recruitment strategy intended to expand the design space for targeted protein degradation.
Source:
They provide an alternative E3 ligase recruitment strategy intended to expand the design space for targeted protein degradation.
provides a KEAP1-based route to targeted protein degradation
LiteratureThey provide an alternative E3 ligase recruitment strategy intended to expand the design space for targeted protein degradation.
Source:
They provide an alternative E3 ligase recruitment strategy intended to expand the design space for targeted protein degradation.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Mechanisms
Degradatione3 ligase recruitmentproteasomal degradationubiquitination-dependent degradationTechniques
Computational DesignTarget processes
degradationInput: Chemical
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: regulatorswitch architecture: recruitment
The abstract indicates that implementation requires KEAP1-binding ligands, with examples from peptide, covalent small-molecule, and non-covalent inhibitor classes.; depends on suitable KEAP1 ligands; future progress requires optimization of KEAP1 ligand properties
The abstract does not claim that current KEAP1-based degraders fully overcome existing challenges, and it explicitly notes that further optimization is needed.; current challenges remain in KEAP1-based targeted protein degradation; further investigation is needed to fully realize therapeutic potential
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
Recent KEAP1-based PROTAC development has targeted BRD4, CDK9, FAK, Tau, and KEAP1 itself.
Recent progress in developing KEAP1-based PROTACs targeting BRD4, CDK9, FAK, Tau and KEAP1 itself is highlighted
KEAP1-recruiting PROTACs have been developed using ligands derived from short peptides, covalent small molecules such as CDDO derivatives, and non-covalent inhibitors such as KI696.
The development of KEAP1- recruiting PROTACs utilizing ligands derived from different classes of known KEAP1 inhibitors-including short peptides, covalent small molecules (e.g., CDDO derivatives), and non-covalent inhibitors (e.g., KI696)-is discussed
Current challenges in KEAP1-based targeted protein degradation remain and require further investigation before full therapeutic potential is realized.
However, current challenges in KEAP1-based targeted protein degradation warrant further investigation to fully realize its therapeutic potential.
Lipid optimization strategies are not discussed; ligand optimization strategies are emphasized to enhance degradation efficacy and specificity in KEAP1-based PROTACs.
with particular emphasis on ligand optimization strategies employed to enhance degradation efficacy and specificity
KEAP1 is identified as a promising E3 ligase candidate for PROTAC design.
Recent advancements have expanded the repertoire of E3 ligases exploitable for PROTAC design, with KEAP1 identified as a promising candidate.
PROTACs are a therapeutic strategy that harnesses the ubiquitin-proteasome system for targeted protein degradation.
Proteolysis-targeting chimeras (PROTACs) have emerged as a novel therapeutic strategy that harnesses the ubiquitin-proteasome system for targeted protein degradation.
Approval Evidence
1 source6 linked approval claimsfirst-pass slug keap1-recruiting-protacs
The development of KEAP1-recruiting PROTACs utilizing ligands derived from different classes of known KEAP1 inhibitors-including short peptides, covalent small molecules (e.g., CDDO derivatives), and non-covalent inhibitors (e.g., KI696)-is discussed.
Source:
application scopesupports
Recent KEAP1-based PROTAC development has targeted BRD4, CDK9, FAK, Tau, and KEAP1 itself.
Recent progress in developing KEAP1-based PROTACs targeting BRD4, CDK9, FAK, Tau and KEAP1 itself is highlighted
Source:
design spacesupports
KEAP1-recruiting PROTACs have been developed using ligands derived from short peptides, covalent small molecules such as CDDO derivatives, and non-covalent inhibitors such as KI696.
The development of KEAP1- recruiting PROTACs utilizing ligands derived from different classes of known KEAP1 inhibitors-including short peptides, covalent small molecules (e.g., CDDO derivatives), and non-covalent inhibitors (e.g., KI696)-is discussed
Source:
limitationsupports
Current challenges in KEAP1-based targeted protein degradation remain and require further investigation before full therapeutic potential is realized.
However, current challenges in KEAP1-based targeted protein degradation warrant further investigation to fully realize its therapeutic potential.
Source:
optimization needsupports
Lipid optimization strategies are not discussed; ligand optimization strategies are emphasized to enhance degradation efficacy and specificity in KEAP1-based PROTACs.
with particular emphasis on ligand optimization strategies employed to enhance degradation efficacy and specificity
Source:
platform potentialsupports
KEAP1 is identified as a promising E3 ligase candidate for PROTAC design.
Recent advancements have expanded the repertoire of E3 ligases exploitable for PROTAC design, with KEAP1 identified as a promising candidate.
Source:
therapeutic modalitysupports
PROTACs are a therapeutic strategy that harnesses the ubiquitin-proteasome system for targeted protein degradation.
Proteolysis-targeting chimeras (PROTACs) have emerged as a novel therapeutic strategy that harnesses the ubiquitin-proteasome system for targeted protein degradation.
Source:
Comparisons
Source-stated alternatives
Within the KEAP1-recruiting design space, the abstract mentions short peptides, CDDO-derived covalent ligands, and KI696-derived non-covalent ligands as alternative recruiter classes.
Source:
Within the KEAP1-recruiting design space, the abstract mentions short peptides, CDDO-derived covalent ligands, and KI696-derived non-covalent ligands as alternative recruiter classes.
Source-backed strengths
supports multiple recruiter ligand classes; review highlights ligand optimization strategies to enhance degradation efficacy and specificity
Source:
supports multiple recruiter ligand classes
Source:
review highlights ligand optimization strategies to enhance degradation efficacy and specificity
Compared with autophagy-targeting chimeras
KEAP1-recruiting PROTACs and autophagy-targeting chimeras address a similar problem space because they share degradation.
Shared frame: same top-level item type; shared target processes: degradation; shared mechanisms: degradation; same primary input modality: chemical
Compared with bacterial degrons
KEAP1-recruiting PROTACs and bacterial degrons address a similar problem space because they share degradation.
Shared frame: same top-level item type; shared target processes: degradation; shared mechanisms: degradation; same primary input modality: chemical
Compared with proteolysis targeting chimera
KEAP1-recruiting PROTACs and proteolysis targeting chimera address a similar problem space because they share degradation.
Shared frame: same top-level item type; shared target processes: degradation; shared mechanisms: degradation; same primary input modality: chemical
Ranked Citations
- 1.